152 related articles for article (PubMed ID: 33830941)
1. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden.
Landwehr LS; Schreiner J; Appenzeller S; Kircher S; Herterich S; Sbiera S; Fassnacht M; Kroiss M; Weigand I
Eur J Endocrinol; 2021 May; 184(6):823-835. PubMed ID: 33830941
[TBL] [Abstract][Full Text] [Related]
2. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.
Pilati C; Shinde J; Alexandrov LB; Assié G; André T; Hélias-Rodzewicz Z; Ducoudray R; Le Corre D; Zucman-Rossi J; Emile JF; Bertherat J; Letouzé E; Laurent-Puig P
J Pathol; 2017 May; 242(1):10-15. PubMed ID: 28127763
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of TP53 alterations in adrenocortical carcinomas.
Waldmann J; Patsalis N; Fendrich V; Langer P; Saeger W; Chaloupka B; Ramaswamy A; Fassnacht M; Bartsch DK; Slater EP
Langenbecks Arch Surg; 2012 Feb; 397(2):209-16. PubMed ID: 22203015
[TBL] [Abstract][Full Text] [Related]
5. Combined steroidogenic characters of fetal adrenal and Leydig cells in childhood adrenocortical carcinoma.
Fujisawa Y; Sakaguchi K; Ono H; Yamaguchi R; Kato F; Kagami M; Fukami M; Ogata T
J Steroid Biochem Mol Biol; 2016 May; 159():86-93. PubMed ID: 26940356
[TBL] [Abstract][Full Text] [Related]
6. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
Fojo T; Huff L; Litman T; Im K; Edgerly M; Del Rivero J; Pittaluga S; Merino M; Bates SE; Dean M
BMC Med Genomics; 2020 Nov; 13(1):165. PubMed ID: 33148256
[TBL] [Abstract][Full Text] [Related]
7. Development of new preclinical models to advance adrenocortical carcinoma research.
Kiseljak-Vassiliades K; Zhang Y; Bagby SM; Kar A; Pozdeyev N; Xu M; Gowan K; Sharma V; Raeburn CD; Albuja-Cruz M; Jones KL; Fishbein L; Schweppe RE; Somerset H; Pitts TM; Leong S; Wierman ME
Endocr Relat Cancer; 2018 Apr; 25(4):437-451. PubMed ID: 29371329
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
9. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
10. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
11. 'You cannot expect miracles to happen overnight': patience pays off when you wish to establish a new adrenocortical carcinoma cell line.
Lalli E
Eur J Endocrinol; 2021 Jul; 185(2):C9-C11. PubMed ID: 34096882
[TBL] [Abstract][Full Text] [Related]
12. Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series.
Creemers SG; Korpershoek E; Atmodimedjo PN; Dinjens WNM; van Koetsveld PM; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2017 Oct; 102(10):3611-3615. PubMed ID: 28973495
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.
Pinto EM; Morton C; Rodriguez-Galindo C; McGregor L; Davidoff AM; Mercer K; Debelenko LV; Billups C; Ribeiro RC; Zambetti GP
Clin Cancer Res; 2013 Apr; 19(7):1740-7. PubMed ID: 23406775
[TBL] [Abstract][Full Text] [Related]
14. A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer.
Viel A; Bruselles A; Meccia E; Fornasarig M; Quaia M; Canzonieri V; Policicchio E; Urso ED; Agostini M; Genuardi M; Lucci-Cordisco E; Venesio T; Martayan A; Diodoro MG; Sanchez-Mete L; Stigliano V; Mazzei F; Grasso F; Giuliani A; Baiocchi M; Maestro R; Giannini G; Tartaglia M; Alexandrov LB; Bignami M
EBioMedicine; 2017 Jun; 20():39-49. PubMed ID: 28551381
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma.
Russell-Swetek A; West AN; Mintern JE; Jenkins J; Rodriguez-Galindo C; Ribeiro R; Zambetti GP
J Med Genet; 2008 Sep; 45(9):603-6. PubMed ID: 18762572
[TBL] [Abstract][Full Text] [Related]
16. HOX genes promote cell proliferation and are potential therapeutic targets in adrenocortical tumours.
Francis JC; Gardiner JR; Renaud Y; Chauhan R; Weinstein Y; Gomez-Sanchez C; Lefrançois-Martinez AM; Bertherat J; Val P; Swain A
Br J Cancer; 2021 Feb; 124(4):805-816. PubMed ID: 33214683
[TBL] [Abstract][Full Text] [Related]
17. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status.
Brenna CTA; Michaeli O; Wasserman JD; Malkin D
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e635-e641. PubMed ID: 33122580
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
Luo Y; Chen Q; Lin J
Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
[TBL] [Abstract][Full Text] [Related]
20. First case report of an adrenocortical carcinoma caused by a BRCA2 mutation.
El Ghorayeb N; Grunenwald S; Nolet S; Primeau V; Côté S; Maugard CM; Lacroix A; Gaboury L; Bourdeau I
Medicine (Baltimore); 2016 Sep; 95(36):e4756. PubMed ID: 27603373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
